Our Braizon is introduced on Nikkei Biotech article
Our platform technology was introduced in a special article on Nikkei Biotech.
Our technology is a non-invasive drug delivery technology to the brain, and our platform technology, glucose transporter 1 of vascular endothelial cells (GLUT1), is used to deliver drugs to the brain through blood glucose control. The point which raises the rate and future prospects are described.
In addition, comments from our polymer scientist Tatebayashi Shinpei are also posted. Please take a look at this article because it shows the trend of DDS technology.
Special feature “Drug delivery technology to the brain that is approaching practical use: Issues that make it difficult to apply animal experiments to humans in the later stages of development of drugs that reach the brain” (October 07, 2019)
(Please note that you must register as a member to view the article.)